🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Tempus AI stock receives notable PT boost from $40 to $70 at Piper Sandler

Published 12/11/2024, 17:12
TEM
-

On Tuesday, Piper Sandler adjusted its outlook on Tempus AI Inc (NASDAQ:TEM), increasing the stock's price target to $70 from the previous $40. The firm maintained a Neutral rating on the shares of the artificial intelligence company. The adjustment follows Tempus AI's recent earnings report, which was a factor in the revised estimates.

The firm's analyst cited the earnings report as the primary reason for the updated price target. Despite the positive adjustment, the analyst noted that the new price target does not include potential impacts from Tempus AI's acquisition of Ambry, a genetics firm. The acquisition's effects on Tempus AI's financials have not been factored into the current estimates.

The reiteration of the Neutral rating alongside the price target increase indicates that, while the firm acknowledges improved performance, it does not necessarily see Tempus AI's stock as outperforming the market at this stage. Investors may interpret this as a signal that the company is on a solid footing, but Piper Sandler remains cautious about its future prospects.

In other recent news, Tempus AI has seen adjustments in its stock price targets by various financial firms following its third-quarter results and the acquisition of Ambry Genetics. Stifel downgraded the stock from Buy to Hold but increased the price target to $65. Needham, on the other hand, raised its stock price target to $56 and maintained its Buy rating.

The acquisition of Ambry Genetics by Tempus AI has been seen as a strategic move, potentially introducing immediate genomics capabilities and promising significant opportunities in data and applications over time. Furthermore, Tempus AI has partnered with Avacta Therapeutics to utilize AI in advancing oncology drug development, providing Avacta access to Tempus's comprehensive multimodal datasets.

Tempus AI's Tempus ECG-AF device, which uses artificial intelligence to identify patients at higher risk of atrial fibrillation/flutter, recently received FDA clearance. These are the recent developments surrounding Tempus AI.

InvestingPro Insights

Tempus AI Inc's recent performance has caught the attention of both analysts and investors. According to InvestingPro data, the company's stock has shown remarkable momentum, with a 74.43% return in just one week and a 92.84% return over the past year. This aligns with Piper Sandler's decision to raise the price target, reflecting the market's growing optimism about Tempus AI's potential.

However, it's important to note that despite the positive stock performance, Tempus AI faces some financial challenges. An InvestingPro Tip indicates that the company is not profitable over the last twelve months, which is supported by the negative operating income of -$692.48 million for the same period. This suggests that while investors are bullish on the company's future prospects, Tempus AI is still in a growth phase and working towards profitability.

Another InvestingPro Tip highlights that Tempus AI is trading at a high revenue valuation multiple. With a market capitalization of $12.22 billion and revenues of $640.44 million in the last twelve months, investors are pricing in significant future growth. This high valuation could explain Piper Sandler's cautious Neutral rating, as the current stock price may already factor in much of the anticipated growth.

For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for Tempus AI, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.